Development of a Bipyrimidineamide based α-Helix Mimetic Lead Compound for efficient Targeting of MDM2 in Triple-Negative Breast Cancer
Jasmin Linh On, Vitalij Woloschin, Franziska Gier, Jia‐Wey Tu, Sanil Bhatia, Thomas Lenz, Andrea Kulik, Kai Stühler, Dieter Niederacher, Hans J. Neubauer, Tanja Natascha Fehm, Thomas Kurz, Knud Esser
This study develops a bipyrimidineamide-based α-helix mimetic compound, VWK603, which effectively targets MDM2 in TNBC cells with lower toxicity than Nutlin-3a.
bioRxiv · Mar 2, 2024 · PreprintCancer Biology